Clinical Trial to Determine Tolerable Dosis of Vorinostat in Patients With Mild Alzheimer Disease
Status:
Recruiting
Trial end date:
2022-03-01
Target enrollment:
Participant gender:
Summary
This Clinical Trial is an open, non-randomized Phase Ib study to determine the maximal
tolerable dose (MTD) of Vorinostat in Alzheimer disease (AD) patients between (including) 55
and 90 years with mild symptoms. The MTD in this study is defined as the dose that leads to
maximum toxicity with Common Toxicity Criteria (CTC) grade 1 symptoms.The safety and
tolerability of Vorinostat in this group of study participants should be tested.
Phase:
Phase 1
Details
Lead Sponsor:
German Center for Neurodegenerative Diseases (DZNE)
Collaborators:
University Hospital, Bonn University of Göttingen